行情

MACK

MACK

Merrimack Pharma
NASDAQ

实时行情|Nasdaq Last Sale

3.250
+0.100
+3.17%
盘后: 3.260 +0.01 +0.31% 17:24 01/17 EST
开盘
3.230
昨收
3.150
最高
3.250
最低
3.050
成交量
2.59万
成交额
--
52周最高
5.51
52周最低
3.050
市值
4,342.98万
市盈率(TTM)
-1.2996
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

MACK 新闻

  • The Daily Biotech Pulse: Osmotica Soars On Insider Buys, Ultragenyx's Partnered Rare Disease Drug Moves Into Clinics
  • Benzinga.1天前
  • Hedge Funds Are Selling Merrimack Pharmaceuticals Inc (MACK)
  • Insider Monkey.2019/12/23 00:44
  • The Daily Biotech Pulse: Axovant Surges On Gene Therapy Study Results, FDA Approves Merck's Ebola Vaccine, Abeona Announces Offering
  • Benzinga.2019/12/20 13:12
  • Merrimack Pharmaceuticals declares $0.50 dividend
  • seekingalpha.2019/12/03 18:49

更多

所属板块

生物技术和医学研究
-0.10%
制药与医学研究
+0.07%

热门股票

名称
价格
涨跌幅

MACK 简况

Merrimack Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in designing novel treatments for cancer by targeting biomarker-defined cancers. Its clinical programs include MM-121 (seribantumab), MM-141 (istiratumab) and MM-310. MM-121 is a fully human monoclonal antibody that binds to the ErbB3 (HER3) receptor and targets heregulin positive cancers. MM-141 is a fully human tetravalent bispecific antibody designed to block tumor survival signals by targeting receptor complexes containing the insulin-like growth factor 1, or IGF-1, receptor and ErbB3 (HER3) cell surface receptor. MM-310 is an antibody-directed nanotherapeutic that targets the ephrin receptor A2, or EphA2, receptor and contains a novel prodrug of the highly potent chemotherapy docetaxel. The Company’s preclinical programs include MM-161, ATRi, BCL2/BCLxl, TRAIL, Immuno-oncology and STIMULI.
展开

Webull提供Merrimack Pharmaceuticals Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。